Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 1.00 |
| ▸ | GRM6 | O15303 | 2/20 | 1.00 |
| ▸ | GRM7 | Q14831 | 2/20 | 1.00 |
| ▸ | GRM4 | Q14833 | 2/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 1/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 1/20 | 1.00 |
| ▸ | GSR | P00390 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GRIK1 | P39086 | 1/20 | 1.00 |
| ▸ | GRM5 | P41594 | 1/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 1/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 1/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 1/20 | 1.00 |
| ▸ | SLC1A3 | P43003 | 1/20 | 1.00 |
| ▸ | SLC1A2 | P43004 | 1/20 | 1.00 |
| ▸ | SLC1A1 | P43005 | 1/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 1/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 1/20 | 1.00 |
| ▸ | GRIK2 | Q13002 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamic Acid SCHEMBL1554237 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL2201 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL1332297 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL1330484 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL931953 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL410241 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| Glutamic Acid SCHEMBL5704264 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL1330824 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL17127348 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL1332144 | 1.00 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228621-A9 | VARIANT IgG FC POLYPEPTIDES AND USES THEREOF | SEISMIC THERAPEUTIC, INC. | 2024-07-11 | — | — | US | claimed |
| US-20240150426-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | Han, Jie (US) | 2024-05-09 | — | — | US | claimed |
| US-20240132592-A1 | VARIANT IgG FC POLYPEPTIDES AND USES THEREOF | SEISMIC THERAPEUTIC INC (US) | 2024-04-25 | — | — | US | claimed |
| CN-117683105-A | Application of eucalyptus grandis dipeptide transporter encoding gene EgNPF8.1 | 华南农业大学 | 2024-03-12 | — | — | CN | claimed |
| WO-2023240022-A2 | CONJUGATE FOR TARGETING CENTRAL NERVOUS SYSTEM | SUNTEC MEDICAL, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| CN-117106189-A | Metal organic framework artificial hydrolase and preparation method and application thereof | 华南理工大学 | 2023-11-24 | — | — | CN | claimed |
| WO-2023219952-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| EP-3077008-B1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (CN) | 2023-10-04 | — | — | EP | claimed |
| CN-116832069-A | Application of lactobacillus plantarum P9 in preparation of medicines for relieving or treating chronic diarrhea or health-care foods for regulating intestinal flora | 江中药业股份有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-112043835-B | Bioreversible introducing group for nitrogen and hydroxyl-containing drugs | 韩捷 | 2022-10-21 | — | — | CN | claimed |
| EP-2270699-A1 | Method for normalization in metabolomics analysis methods with endogenous reference metabolites | BIOCRATES Life Sciences AG (AT) | 2011-01-05 | — | — | EP | claimed |
| US-20100144645-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ANALGESIC POTENCY OF COVALENTLY BOUND-COMPOUNDS, ATTENUATING ITS ADVERSE SIDE EFFECTS, AND PREVENTING THEIR ABUSE | SHIRE LLC (US) | 2010-06-10 | — | — | US | claimed |
| EP-1807467-B1 | PROCESSES FOR PREPARING GLATIRAMER | SANDOZ AG (CH) | 2009-08-26 | — | — | EP | claimed |
| CN-101437517-A | Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse | SHIRE LLC (US) | 2009-05-20 | — | — | CN | claimed |
| EP-2007389-A2 | COMPOSITIONS AND METHODS FOR ENHANCING ANALGESIC POTENCY OF COVALENTLY BOUND COMPOUNDS, ATTENUATING ITS ADVERSE SIDE EFFECTS, AND PREVENTING THEIR ABUSE | Shire LLC (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007120864-A2 | COMPOSITIONS AND METHODS FOR ENHANCING ANALGESIC POTENCY OF COVALENTLY BOUND COMPOUNDS, ATTENUATING ITS ADVERSE SIDE EFFECTS, AND PREVENTING THEIR ABUSE | SHIRE LLC (US) | 2007-10-25 | — | — | WO | claimed |
| EP-1807467-A1 | PROCESSES FOR PREPARING GLATIRAMER | Sandoz AG (CH) | 2007-07-18 | — | — | EP | claimed |
| US-20060154862-A1 | Processes for preparing a polypeptide | SANDOZ AG (CH) | 2006-07-13 | — | — | US | claimed |
| WO-2006050122-A1 | PROCESSES FOR PREPARING GLATIRAMER | SANDOZ AG (CH) | 2006-05-11 | — | — | WO | claimed |
| CN-1700930-A | Methods and reagents relating to inflammation and apoptosis | WYETH CORP (US) | 2005-11-23 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144645-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ANALGESIC POTENCY OF COVALENTLY BOUND-COMPOUNDS, ATTENUATING ITS ADVERSE SIDE EFFECTS, AND PREVENTING THEIR ABUSE | OPRK1, OPRL1, OPRM1 | GRM8 135/4885GRM6 128/4885GRM7 180/4885 |
| US-20240150426-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | GRM8 3384/4885GRM6 2326/4885GRM7 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.